Milestone-Based Engagement
Milestone-Based Engagement
The Model:
- Highly structured, rigidly scoped projects where progress and payments are tied exclusively to predefined scientific or regulatory deliverables (e.g., successful assay qualification or specific data readouts).
Best For:
- Validating a single assay, processing a finite clinical cohort, or achieving a specific data inflection point for investor funding.
Risk-Sharing & Co-Development
The Model:
- A joint venture structure where we absorb a portion of the upfront development costs in exchange for shared downstream value (royalties, revenue sharing, or joint IP) upon clinical success.
Best For:
- Early-stage biotechs advancing highly novel, promising therapeutics where early capital is tight but the scientific potential is exceptional.
Strategic Alliance (Preferred Provider)
The Model:
- A long-term Master Service Agreement (MSA) that locks in preferred pricing, guarantees instrument capacity, and standardizes workflows across all your future projects, eliminating administrative bottlenecks.
Best For:
- Mid-to-large biopharma organizations managing robust, multi-asset pipelines requiring a reliable, high-tier analytical partner.
The Virtual Biotech "Backbone"
The Model:
- We serve as your complete, outsourced laboratory engine. While your leadership focuses on IP, capital allocation, and regulatory strategy, we handle the entire continuum of preclinical and analytical execution.
Best For:
- Asset-light biotech startups operating without physical lab space or internal technical staff, requiring immediate, credible R&D infrastructure.
